Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia
Data Collection
Infections+2
+ Lung Diseases
+ Pneumonia
Treatment Study
Summary
Study start date: May 1, 2004
Actual date on which the first participant was enrolled.The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.2136 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and management Exclusion Criteria: * Pregnancy * Weight over 150 kg * Patients at increased risk of bleeding * Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa * Treatment with heparin or anticipated need for heparin
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location